Invesco Ltd. Purchases 282,532 Shares of Encompass Health Corporation (NYSE:EHC)

Key Points

• Invesco Ltd. increased its stake in Encompass Health Corporation by 5.1% in Q1, owning approximately 5.77% of the company, valued at $589.3 million.
• Encompass Health's CEO Mark J. Tarr sold 118,384 shares at an average price of $121.53, decreasing his ownership by 18.34% to 527,070 shares.
• Analysts have a consensus rating of "Buy" for Encompass Health, with price targets increased by several firms, now averaging around $133.17.

Invesco Ltd. grew its position in shares of Encompass Health Corporation (NYSE:EHC - Free Report) by 5.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,818,783 shares of the company's stock after buying an additional 282,532 shares during the period. Invesco Ltd. owned approximately 5.77% of Encompass Health worth $589,326,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in EHC. T. Rowe Price Investment Management Inc. bought a new position in Encompass Health during the 4th quarter worth $152,953,000. Farallon Capital Management LLC increased its position in shares of Encompass Health by 15,266.7% in the fourth quarter. Farallon Capital Management LLC now owns 461,000 shares of the company's stock worth $42,573,000 after purchasing an additional 458,000 shares during the period. AQR Capital Management LLC increased its position in shares of Encompass Health by 136.8% in the fourth quarter. AQR Capital Management LLC now owns 689,206 shares of the company's stock worth $63,648,000 after purchasing an additional 398,154 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Encompass Health by 22.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,610,669 shares of the company's stock worth $148,746,000 after purchasing an additional 300,386 shares during the period. Finally, Fuller & Thaler Asset Management Inc. increased its position in shares of Encompass Health by 24.8% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 1,378,077 shares of the company's stock worth $127,265,000 after purchasing an additional 274,192 shares during the period. Institutional investors own 97.25% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently commented on EHC. Barclays raised their price target on Encompass Health from $118.00 to $129.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Wall Street Zen cut Encompass Health from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. Stephens upgraded Encompass Health from an "overweight" rating to a "strong-buy" rating and set a $135.00 target price on the stock in a research report on Thursday, June 5th. KeyCorp lifted their target price on Encompass Health from $122.00 to $135.00 and gave the company an "overweight" rating in a research report on Tuesday, May 27th. Finally, Truist Financial set a $140.00 target price on Encompass Health and gave the company a "buy" rating in a research report on Thursday. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $134.00.

Encompass Health Trading Up 0.5%

Shares of Encompass Health stock traded up $0.59 during midday trading on Thursday, reaching $119.72. The company had a trading volume of 259,162 shares, compared to its average volume of 820,293. The stock has a fifty day moving average price of $116.19 and a 200 day moving average price of $109.14. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.06 and a quick ratio of 1.06. The firm has a market cap of $12.06 billion, a PE ratio of 23.40, a P/E/G ratio of 2.07 and a beta of 0.86. Encompass Health Corporation has a fifty-two week low of $87.36 and a fifty-two week high of $123.13.

Encompass Health (NYSE:EHC - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported $1.40 EPS for the quarter, topping analysts' consensus estimates of $1.20 by $0.20. The company had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. Encompass Health had a return on equity of 17.83% and a net margin of 9.22%. The firm's quarterly revenue was up 12.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.11 earnings per share. On average, equities analysts anticipate that Encompass Health Corporation will post 4.8 earnings per share for the current year.

Encompass Health Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Wednesday, October 1st will be paid a $0.19 dividend. This is an increase from Encompass Health's previous quarterly dividend of $0.17. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Wednesday, October 1st. Encompass Health's payout ratio is presently 13.31%.

Insider Activity at Encompass Health

In other Encompass Health news, CEO Mark J. Tarr sold 118,384 shares of Encompass Health stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $121.53, for a total value of $14,387,207.52. Following the completion of the sale, the chief executive officer directly owned 527,070 shares in the company, valued at approximately $64,054,817.10. The trade was a 18.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.00% of the stock is currently owned by corporate insiders.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.